This Unloved Drug Stock Could Have Massive Upside

Aurinia Pharmaceuticals Inc. (TSX:AUP)(NASDAQ:AUPH) is over-priced, but should that stop you owning one of the most stable high-growth stocks on the TSX?

| More on:
The Motley Fool

Not all drug stocks are pot stocks on the TSX! Here’s a pharmaceutical stock (remember those?) that’s currently overlooked, but that could have massive upside.

It’s one that value investors have been giving some serious side-eye, but the fact is that the following stock is a high-growth superstar stock that anyone looking to make some serious capital gains on the TSX might want to check out.

Aurinia Pharmaceuticals Inc. (TSX:AUP)(NASDAQ:AUPH)

Overvalued by almost eight times its future cash flow value, Aurinia Pharmaceuticals isn’t what you might call a value purchase right now. As it’s currently loss making, its forward-looking multiples are somewhat opaque, though we are able to see from its P/B ratio that Aurinia Pharmaceuticals is trading at 3.1 times its book price.

While past performance has been poor, Aurinia Pharmaceuticals has a whopping 71.7% expected annual growth in earnings ahead of it.

It’s also an extremely healthy stock, with very little in the way of unsold physical assets and no debt at all. If you’re looking for high growth and want a flawless balance sheet to go with it, Aurinia Pharmaceuticals delivers the goods.

TSX and drugs and rock ’n’ roll

Talk about your high-growth rockstars: Aurinia Pharmaceuticals is it. It’s not a dividend payer yet, but looking at a huge growth spurt, Aurinia Pharmaceuticals is the biggest clinical stage biopharmaceutical stock you haven’t heard of. It’s active in the research, development, and sales of therapeutic solutions for treating autoimmune diseases.

Servicing markets in Canada, the U.S., China, and Switzerland, Aurinia Pharmaceuticals is geographically diversified, although potential investors should see this stock as a pure play autoimmune disease drug stock.

With a focus on the worldwide immunology drugs market, Aurinia Pharmaceuticals is currently undertaking second phase trials to evaluate Aurinia Pharmaceuticals’ Voclosporin ophthalmic solution as a treatment for dry eye syndrome. Once accepted on the market for DES, Voclosporin would add large swathes of revenue for Aurinia Pharmaceuticals.

There’s all kinds of overvaluation going on for Aurinia Pharmaceuticals, however, which is something of a shame for patient investors who have been waiting for share price to improve. Unfortunately, buying Aurinia Pharmaceuticals at today’s price would be a bitter pill to swallow.

The bottom line

Let’s go back to that overvaluation. Is it realistic to think that Aurinia Pharmaceuticals will ever drop below a dollar a stock? In the past five years, its lowest point was $2.70, after which it leaped to almost $12. If you were to get in at its current price of $7.51, you could still see a massive income once that +70% annual growth in earnings starts rolling in.

Analysts are giving a moderate to strong buy signal, and given that still fairly cheap stock price and he growth curve, it’s easy to see why. If you’re light on pharma stocks and want a serious contender outside all of these speculative small-cap biotech shares, Aurinia Pharmaceuticals is a good choice to stash and hold for long-term gains.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Victoria Hetherington has no position in any of the stocks mentioned.

More on Investing

ETF stands for Exchange Traded Fund
Dividend Stocks

How to Earn $2,000 in Passive Income in 2025 With Less Than $51,000 in Savings

You can invest in Canadian high yield stocks via the Vanguard FTSE Canadian High Yield Dividend ETF (TSX:VDY).

Read more »

Asset Management
Investing

Where Will Restaurant Brands International Stock Be in 1/3/5 Years?

Let's dive into where Restaurant Brands (TSX:QSR) could be headed over the near to medium term, shall we?

Read more »

profit rises over time
Tech Stocks

4 Reasons to Buy Constellation Software Stock Like There’s No Tomorrow

Constellation Software stock continued its climb upwards after recent earnings, and this only adds to its appeal.

Read more »

Trans Alaska Pipeline with Autumn Colors
Energy Stocks

Is Enbridge Stock a Good Buy?

Enbridge provides a 6.5% dividend yield right now.

Read more »

calculate and analyze stock
Bank Stocks

Is National Bank of Canada Stock a Buy for its 3.3% Dividend Yield?

While National Bank stock might seem to have a lower dividend yield, its upside could offer a valuable way to…

Read more »

An investor uses a tablet
Investing

4 Value Stocks That Are Must Buys for Canadians in November

Whether you want to add growth or defence to your portfolio, these four stocks are some of the best Canadian…

Read more »

Oil industry worker works in oilfield
Energy Stocks

Is Suncor Stock a Buy, Sell, or Hold for 2025?

Suncor stock looks undervalued as the company continues to increases cash flows, earnings, and shareholder returns.

Read more »

monthly desk calendar
Dividend Stocks

This 7.8% Dividend Stock Pays Out Every Month

Not all monthly dividend stocks are created equal. And this top stock is certainly a strong choice for passive income.

Read more »